Explore the latest in targeted and immune therapies, including recent advances in precision therapies and in use of tumor checkpoint inhibitors.
This phase 2, multi-institutional clinical trial assesses whether patients with resected primary gastrointestinal stromal tumor receiving 5 years of adjuvant imatinib mesylate therapy have improved recurrence-free survival and overall survival compared with patients receiving a shorter duration of therapy in previous studies.
This study explores the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer (NSCLC) in the context of the US health care system.
This randomized clinical trial assesses the efficacy and safety of continuous bevacizumab treatment plus standard of care vs standard of care alone beyond first progression in patients with non–small cell lung cancer.
This cohort study assesses self-reported quality of life among patients referred to oncodermatology clinics for pruritus associated with immunotherapy.
This systematic review and meta-analysis examines randomized clinical trials (RCTs) of modern cancer drugs in the adjuvant setting to determine the incidence of severe adverse events reported in placebo groups.
This Viewpoint reviews recent preclinical developments in the use of therapeutic cancer vaccines to induce immune responses to tumor-associated antigens, alone or in combination with other therapies, such as tumor checkpoint inhibitor monoclonal antibodies, to render resistant (cold) tumor cells susceptible to T-cell antitumor activity.
This cost-effectiveness analysis uses a decision analytic model to extrapolate trial evidence to estimate the long-term survival and value of tisagenlecleucel for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
This narrative review describes targeted alpha therapy and reviews the rationale and considerations for its development and implementation as a viable treatment strategy in oncology.
This systematic review and meta-analysis analyzes the incidence of regimen-specific fatal toxic effects associated with the use of immune checkpoint inhibitors for cancer treatment.
This case report describes metastatic calcinosis cutis associated with selective FGFR inhibitor therapy.
This narrative review discusses the rationale and results of clinical trials in immunotherapy-based combination therapy for patients with advanced renal cell carcinoma.
This economic evaluation assesses the cost-effectiveness of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma from the perspective of public and private US payers.
This cohort study investigates possible mechanisms underlying primary resistance to immune checkpoint inhibitors of metastatic colorectal cancers displaying microsatellite instability or mismatch repair deficiency.
This Viewpoint discusses the initials results of the NCI-MATCH trial, a phase 2 study that seeks to determine whether targeted therapies for specific gene mutations will lead to objective responses agnostic to the primary cancer type.
This biomarker study estimates the diversity of T-cell populations in the tumor microenvironment by assessing messenger RNA expression of the T-cell receptor β chain variable gene from RNA sequencing data of pretreatment biopsies of women with HER2-positive breast cancer in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial.
This case series describes 2 patients who developed ophthalmologic events after treatment with the programmed death 1 axis inhibitor, atezolizumab.
This cohort study describes the use of programmed cell death 1 inhibitors for the treatment of metastatic conjunctival melanoma in 5 adult patients.
This phase 2 randomized clinical trial compare the efficacy and toxicity profiles of durvalumab monotherapy and tremelimumab monotherapy against a combination of both in patients with recurrent or metastatic head and neck squamous cell carcinoma with low or no expression of programmed death ligand 1.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: